Active Ingredient History
Epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, is the ester of epigallocatechin and gallic acid, and is a type of catechin. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Affect (Phase 4)
Alzheimer Disease (Phase 2/Phase 3)
Amyloidosis (Phase 2)
Angina, Stable (Phase 2)
Arthritis, Rheumatoid (Phase 3)
Autoimmune Diseases (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Squamous Cell (Phase 3)
Cardiovascular Diseases (Phase 2)
Cognition (Phase 4)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 3)
Dermatitis (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Diabetic Nephropathies (Phase 2)
Diabetic Retinopathy (Phase 1)
Down Syndrome (Phase 2)
Drugs, Investigational (Phase 2)
Endometriosis (Phase 2)
Esophagitis (Phase 2)
Fetal Alcohol Spectrum Disorders (Phase 3)
Frailty (Phase 2)
Glaucoma, Open-Angle (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 1)
Heart Diseases (Phase 2)
Hepatitis C, Chronic (Phase 1)
Huntington Disease (Phase 2)
Hypercholesterolemia (Phase 2)
Hyperlipidemias (Phase 3)
Hypertension (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Inflammation (Phase 2)
Insulin Resistance (Phase 2)
Leiomyoma (Phase 2)
Lichen Planus, Oral (Phase 3)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Metabolism (Phase 4)
Mucositis (Phase 2)
Multiple Sclerosis (Phase 2/Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 1/Phase 2)
Multiple System Atrophy (Phase 3)
Muscular Dystrophy, Duchenne (Phase 2/Phase 3)
Nasopharyngeal Carcinoma (Phase 3)
Neoplasms (Phase 1)
Obesity (Phase 3)
Ocular Hypertension (Phase 1/Phase 2)
Osteoporosis (Phase 1/Phase 2)
Oxidative Stress (Phase 1)
Parkinson Disease (Phase 2)
Prostatic Neoplasms (Phase 2/Phase 3)
Radiodermatitis (Phase 2)
Small Cell Lung Carcinoma (Phase 1)
Tuberculosis (Phase 1)
Weight Loss (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue